# A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

> **NCT02722135** · PHASE1 · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Volasertib

## Key facts

- **NCT ID:** NCT02722135
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2018-05
- **Final completion:** 2018-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02722135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02722135, "A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02722135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*